This bill directs the Department of Health and Human Services to create a demonstration program that gives preferential treatment to medications and biological products manufactured in the United States when covering drugs under Medicare, Medicaid, and the Children's Health Insurance Program. The program will run for at least seven years across at least eight states and will use various tools to prioritize American-made drugs, such as placing them on preferred medication lists, lowering patient cost-sharing, or providing bonus payments to healthcare providers. The bill focuses on both generic drugs and critical medicines needed for public health emergencies or vulnerable to supply chain disruptions, and participating manufacturers must meet certain requirements including maintaining U.S. manufacturing locations and sourcing at least half their raw materials from non-covered nations after three years. The Secretary must begin the program within one year of the bill's enactment and submit annual reports to Congress on its progress and recommendations. The legislation authorizes whatever funding is necessary to administer the program, though no specific dollar amount is specified.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.